These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

748 related articles for article (PubMed ID: 36318381)

  • 1. Emerging strategies: PARP inhibitors in combination with immune checkpoint blockade in BRCA1 and BRCA2 mutation-associated and triple-negative breast cancer.
    Gupta T; Vinayak S; Telli M
    Breast Cancer Res Treat; 2023 Jan; 197(1):51-56. PubMed ID: 36318381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor Intrinsic PD-L1 Promotes DNA Repair in Distinct Cancers and Suppresses PARP Inhibitor-Induced Synthetic Lethality.
    Kornepati AVR; Boyd JT; Murray CE; Saifetiarova J; de la Peña Avalos B; Rogers CM; Bai H; Padron AS; Liao Y; Ontiveros C; Svatek RS; Hromas R; Li R; Hu Y; Conejo-Garcia JR; Vadlamudi RK; Zhao W; Dray E; Sung P; Curiel TJ
    Cancer Res; 2022 Jun; 82(11):2156-2170. PubMed ID: 35247877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Homologous Recombination Defects and Mutations in DNA Damage Response (DDR) Genes Besides
    Voutsadakis IA; Stravodimou A
    Anticancer Res; 2023 Mar; 43(3):967-981. PubMed ID: 36854505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining poly(ADP-ribose) polymerase inhibitors and immune checkpoint inhibitors in breast cancer: rationale and preliminary clinical results.
    Goncalves A; Mezni E; Bertucci F
    Curr Opin Oncol; 2020 Nov; 32(6):585-593. PubMed ID: 32852311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of BRCA1- and BRCA2-deficiency with mutation burden, expression of PD-L1/PD-1, immune infiltrates, and T cell-inflamed signature in breast cancer.
    Wen WX; Leong CO
    PLoS One; 2019; 14(4):e0215381. PubMed ID: 31022191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
    Strickland KC; Howitt BE; Shukla SA; Rodig S; Ritterhouse LL; Liu JF; Garber JE; Chowdhury D; Wu CJ; D'Andrea AD; Matulonis UA; Konstantinopoulos PA
    Oncotarget; 2016 Mar; 7(12):13587-98. PubMed ID: 26871470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRCA1 deficiency is a recurrent event in early-onset triple-negative breast cancer: a comprehensive analysis of germline mutations and somatic promoter methylation.
    Brianese RC; Nakamura KDM; Almeida FGDSR; Ramalho RF; Barros BDF; Ferreira ENE; Formiga MNDC; de Andrade VP; de Lima VCC; Carraro DM
    Breast Cancer Res Treat; 2018 Feb; 167(3):803-814. PubMed ID: 29116469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triple‑negative breast cancer therapy: Current and future perspectives (Review).
    Won KA; Spruck C
    Int J Oncol; 2020 Dec; 57(6):1245-1261. PubMed ID: 33174058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exceptional responses to PARP inhibitors in patients with metastatic breast cancer in oncologic crisis.
    Cheng JM; Canzoniero J; Lee S; Soni S; Mangini N; Santa-Maria CA
    Breast Cancer Res Treat; 2023 Jun; 199(2):389-397. PubMed ID: 37002487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRCA1 and BRCA2 deficient tumour models generate distinct ovarian tumour microenvironments and differential responses to therapy.
    Farokhi Boroujeni S; Rodriguez G; Galpin K; Yakubovich E; Murshed H; Ibrahim D; Asif S; Vanderhyden BC
    J Ovarian Res; 2023 Nov; 16(1):231. PubMed ID: 38017453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.
    Isaacs J; Anders C; McArthur H; Force J
    Curr Treat Options Oncol; 2021 Mar; 22(5):38. PubMed ID: 33743085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of mutation status and homologous recombination deficiency in tumors of patients with germline BRCA1 or BRCA2 mutations and metastatic breast cancer: OlympiAD.
    Hodgson D; Lai Z; Dearden S; Barrett JC; Harrington EA; Timms K; Lanchbury J; Wu W; Allen A; Senkus E; Domchek SM; Robson M
    Ann Oncol; 2021 Dec; 32(12):1582-1589. PubMed ID: 34500047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRCA1/2 signaling and homologous recombination deficiency in breast and ovarian cancer.
    Royfman R; Whiteley E; Noe O; Morand S; Creeden J; Stanbery L; Hamouda D; Nemunaitis J
    Future Oncol; 2021 Jul; 17(21):2817-2830. PubMed ID: 34058833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PARP Inhibitors in Triple-Negative Breast Cancer Including Those With BRCA Mutations.
    Layman RM; Arun B
    Cancer J; 2021 Jan-Feb 01; 27(1):67-75. PubMed ID: 33475295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The recent advances of PD-1 and PD-L1 checkpoint signaling inhibition for breast cancer immunotherapy.
    Setordzi P; Chang X; Liu Z; Wu Y; Zuo D
    Eur J Pharmacol; 2021 Mar; 895():173867. PubMed ID: 33460617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in PARP inhibitors for the treatment of breast cancer.
    Dizdar O; Arslan C; Altundag K
    Expert Opin Pharmacother; 2015; 16(18):2751-8. PubMed ID: 26485111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models.
    Wang Z; Sun K; Xiao Y; Feng B; Mikule K; Ma X; Feng N; Vellano CP; Federico L; Marszalek JR; Mills GB; Hanke J; Ramaswamy S; Wang J
    Sci Rep; 2019 Feb; 9(1):1853. PubMed ID: 30755715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential Activity of PARP Inhibitors in
    Taza F; Holler AE; Fu W; Wang H; Adra N; Albany C; Ashkar R; Cheng HH; Sokolova AO; Agarwal N; Kessel A; Bryce A; Nafissi N; Barata P; Sartor AO; Bastos D; Smaletz O; Berchuck JE; Taplin ME; Aggarwal R; Sternberg CN; Vlachostergios PJ; Alva AS; Su C; Marshall CH; Antonarakis ES
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34778690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside.
    Turk AA; Wisinski KB
    Cancer; 2018 Jun; 124(12):2498-2506. PubMed ID: 29660759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of novel poly (ADP-ribose) inhibitors in the treatment of locally advanced and metastatic Her-2/neu negative breast cancer with inherited germline BRCA1/2 mutations. A review of the literature.
    Pop L; Suciu I; Ionescu O; Bacalbasa N; Ionescu P
    J Med Life; 2021; 14(1):17-20. PubMed ID: 33767780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.